RT Journal Article
T1 Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial
A1 Sánchez Barrueco, Álvaro
A1 Mateos Moreno, María Victoria
A1 Martínez-Beneyto, Yolanda
A1 García-Vázquez, Elisa
A1 Campos González, Alfonso
A1 Zapardiel Ferrero, Javier
A1 Bogoya Castaño, Abel
A1 Alcalá Rueda, Ignacio
A1 Villacampa Aubá, José Miguel
A1 Cenjor Español, Carlos
A1 Moreno-Parrado, Laura
A1 Ausina-Márquez, Verónica
A1 García-Esteban, Sandra
A1 Artacho, Alejandro
A1 López-Labrador, F Xavier
A1 Mira Obrador, Alejandro
A1 Ferrer García, María Desamparados
AB Background: In vitro studies have shown that several oral antiseptics have virucidal activity against SARS-CoV-2. Thus, mouthwashes have been proposed as an easy to implement strategy to reduce viral transmission. However, there are no data measuring SARS-CoV-2 viability after mouthwashes in vivo.Methods: In this randomized double-blind, five-parallel-group, placebo-controlled clinical trial, SARS-CoV-2 salivary viral load (by quantitative PCR) and its infectious capacity (incubating saliva in cell cultures) have been evaluated before and after four different antiseptic mouthwashes and placebo in 54 COVID-19 patients.Results: Contrary to in vitro evidence, salivary viral load was not affected by any of the four tested mouthwashes. Viral culture indicated that cetylpyridinium chloride (CPC) significantly reduced viral infectivity, but only at 1-hour post-mouthwash.Conclusion: These results indicate that some of the mouthwashes currently used to reduce viral infectivity are not efficient in vivo and, furthermore, that this effect is not immediate, generating a false sense of security.Trial registration: ClinicalTrials.gov identifier: NCT04707742..
PB Taylor & Francis
YR 2022
FD 2022-07
LK https://hdl.handle.net/20.500.14352/117176
UL https://hdl.handle.net/20.500.14352/117176
LA eng
NO Sánchez Barrueco Á, Mateos-Moreno MV, Martínez-Beneyto Y, García-Vázquez E, Campos González A, Zapardiel Ferrero J, Bogoya Castaño A, Alcalá Rueda I, Villacampa Aubá JM, Cenjor Español C, Moreno-Parrado L, Ausina-Márquez V, García-Esteban S, Artacho A, López-Labrador FX, Mira A, Ferrer MD. Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial. Emerg Microbes Infect. 2022 Dec;11(1):1833-1842. doi: 10.1080/22221751.2022.2098059
NO FISABIO Project UGP-21-438, financed by Consellería de Sanitat Universal i Salut Pública from the Valencian Region and by the European Regional Development Fund and European Social Fund.
DS Docta Complutense
RD 17 abr 2025